HC Wainwright Predicts ProKidney’s Q2 Earnings (NASDAQ:PROK)

ProKidney Corp. (NASDAQ:PROK) – Analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of ProKidney in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.13) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at ($0.34) EPS.

ProKidney (NASDAQ:PROK) last posted its earnings results on Wednesday, March 18th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.00 million.

A number of other equities research analysts have also weighed in on PROK. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research report on Thursday, January 22nd. Wall Street Zen lowered ProKidney from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Jefferies Financial Group upgraded ProKidney to a “strong-buy” rating in a report on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

ProKidney Stock Performance

Shares of PROK opened at $1.79 on Monday. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.13. The stock has a market capitalization of $538.49 million, a price-to-earnings ratio of -3.44 and a beta of 1.75. The stock has a fifty day moving average of $2.13 and a 200-day moving average of $2.42.

Institutional Trading of ProKidney

Institutional investors have recently modified their holdings of the business. Cetera Investment Advisers acquired a new stake in ProKidney in the fourth quarter valued at $28,000. Zullo Investment Group Inc. acquired a new position in ProKidney during the 3rd quarter worth about $28,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of ProKidney in the 2nd quarter valued at about $36,000. AQR Capital Management LLC grew its position in shares of ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after buying an additional 27,098 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in shares of ProKidney in the fourth quarter valued at about $65,000. Institutional investors own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.